Within the clinical demo practical experience with Xyrem in narcolepsy/cataplexy sufferers at therapeutic doses, two clients documented stress and a person described insomnia subsequent abrupt discontinuation at the termination on the clinical trial; in The 2 sufferers with anxiety, the frequency of cataplexy had improved markedly concurrently.To p